Rx Medicare

QRxPharma Limited (Pink Sheets: QRXPY; ASX: QRX) announced the initiation of a Phase 2 comparative proof-of-concept study to evaluate the efficacy and safety of MoxDuo(TM) IV (intravenous morphine and oxycodone) versus IV morphine alone for the treatment of moderate to severe post-operative pain in patients following hip replacement surgery.

Read More…

Related Posts

• QRxPharma Initiates Second Comparative Study For MoxDuo(TM) IR Dual-Opioid(TM) Pain Therapy
• QRxPharma Initiates Pivotal Phase 3 Study Of MoxDuo(TM)IR For Moderate To Severe Acute Pain
• QRxPharma Successfully Completes Comparative Study For Dual-Opioid(TM) Pain Therapy
• QRxPharma Initiates Second Pivotal Phase 3 Study Of MoxDuo(TM)IR Dual-Opioid(TM) For NDA Submission
• KAI Pharmaceuticals Initiates Third Phase 2a Study In Program To Develop KAI-1678 For The Treatment Of Neuropathic Pain
• Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of … – PR Newswire (press release)
• China Aoxing Pharmaceutical Company Announces Successful Completion Of Phase II Clinical Study Of Novel Menstrual Pain Drug
• Pacira’s Phase III Study Of EXPAREL(TM) Meets Primary Pain Relief Endpoint
• Transdel Pharmaceuticals Announces Positive Phase 3 Study Results For Lead Topical Pain Drug Ketotransdel(R)
• Extracorporeal Shock Wave Therapy For The Treatment Of Chronic Pelvic Pain Syndrome In Males: A Randomised, Double-Blind, Placebo-Controlled Study
• AcelRx Announces Positive Phase 2 Results From A Study Of ARX-01 Sufentanil NanoTabs In Treating Post-Operative Pain
• Competitive Technologies’ Pain Therapy Medical Device To Be Used In Independent Clinical Study
• PAION Initiates Phase Ib Study Of The Anesthetic/Sedative CNS 7056 In Volunteers Undergoing Colonoscopy
• KAI Pharmaceuticals Expands KAI-1678 Development Program, Initiating A Phase 2a Study For Neuropathic Pain
• Cerimon Pharmaceuticals Initiates Phase III Clinical Studies To Evaluate Its Topical Diclofenac Sodium Patch For Mild-to-Moderate Pain

Tags: comparative, concept, initiates, moxduotm, pain, phase, proof, qrxpharma, study, therapy

This entry was posted on Thursday, July 30th, 2009 at 6:07 pm and is filed under Analgesics Pain Migraine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.